Current Clinical Microbiology Reports最新文献_第4页

Is There a Relationship Between Mating and Pathogenesis in Two Human Fungal Pathogens, Candida albicans and Candida glabrata? 两种人类真菌病原体白色念珠菌和光滑念珠菌的交配和发病机制之间有关系吗？

IF 3.1

Current Clinical Microbiology Reports Pub Date : 2023-01-01 Epub Date: 2023-04-22 DOI: 10.1007/s40588-023-00192-8

Tina Bedekovic, Jane Usher

{"title":"Is There a Relationship Between Mating and Pathogenesis in Two Human Fungal Pathogens, Candida albicans and Candida glabrata?","authors":"Tina Bedekovic, Jane Usher","doi":"10.1007/s40588-023-00192-8","DOIUrl":"10.1007/s40588-023-00192-8","url":null,"abstract":"Purpose of review: Human fungal pathogens are rapidly increasing in incidence and readily able to evade the host immune responses. Our ability to study the genetic behind this has been limited due to the apparent lack of a sexual cycle and forward genetic tools. In this review, we discuss the evolution of mating, meiosis, and pathogenesis and if these processes are advantageous to pathogens.Recent findings: This review summarises what is currently known about the sexual cycles of two important human fungal pathogens, Candida albicans and Candida glabrata. This includes the identification of parasexual cycle in C. albicans and the observed low levels of recombination in C. glabrata populations.Summary: In this review, we present what is currently known about the mating types and mating/sexual cycles of two clinically important human fungal pathogens, Candida albicans and Candida glabrata. We discuss the evolution of meiosis using the knowledge that has been amassed from the decades of studying Saccharomyces cerevisiae and how this can be applied to fungal pathogens. We further discuss how the evolution of pathogenesis has played a role in influencing mating processes in human fungal pathogens and compare sexual cycles between C. albicans and C. glabrata, highlighting knowledge gaps and suggesting how these two fungi have evolved distinct mating niches to allow the development of disease in a human host.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"10 2","pages":"47-54"},"PeriodicalIF":3.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9431484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Host and Environmental Sensing by Entomopathogenic Fungi to Infect Hosts 寄主与昆虫病原真菌对寄主的环境感知

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-10-29 DOI: 10.1007/s40588-022-00185-z

Jun-mei Shang, Guirong Tang, Mengting Lu, Chengshu Wang

引用次数: 4

Selection of Relevant Bacterial Strains for Novel Therapeutic Testing: a Guidance Document for Priority Cystic Fibrosis Lung Pathogens 新型治疗试验相关菌株的选择:肺囊性纤维化优先病原菌的指导文件

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-10-14 DOI: 10.1007/s40588-022-00182-2

E. Mahenthiralingam, R. Weiser, R. Floto, J. Davies, J. Fothergill

引用次数: 1

Microbial Interplay in Skin and Chronic Wounds 皮肤和慢性伤口中的微生物夹层

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-08-06 DOI: 10.1007/s40588-022-00180-4

Chandni Sachdeva, K. Satyamoorthy, T. S. Murali

引用次数: 4

Correction to: Germination of a Field: Women in Candida albicans Research 修正:一个领域的萌芽:女性在白色念珠菌研究

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-03-10 DOI: 10.1007/s40588-022-00176-0

Faith M. Anderson, Elizabeth J. Polvi, Amanda O. Veri, Teresa R. O’Meara

引用次数: 0

Correction to: A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists 更正:球虫研究综述、领域内的突出问题和女科学家的贡献

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-03-01 DOI: 10.1007/s40588-022-00177-z

M. Gorris, M. V. Van Dyke, A. Carey, Paris S. Hamm, Heather L. Mead, J. Uehling

引用次数: 0

Emerging Fungal Infections: from the Fields to the Clinic, Resistant Aspergillus fumigatus and Dermatophyte Species: a One Health Perspective on an Urgent Public Health Problem. 新出现的真菌感染：从田间到临床》，《耐药曲霉菌和皮癣菌种：从单一健康视角看待亟待解决的公共健康问题》，《新出现的真菌感染：从田间到临床》，《耐药曲霉菌和皮癣菌种：从单一健康视角看待亟待解决的公共健康问题》。

IF 3.1

Current Clinical Microbiology Reports Pub Date : 2022-01-01 Epub Date: 2022-09-27 DOI: 10.1007/s40588-022-00181-3

Antonia Langfeldt, Jeremy A W Gold, Tom Chiller

{"title":"Emerging Fungal Infections: from the Fields to the Clinic, Resistant Aspergillus fumigatus and Dermatophyte Species: a One Health Perspective on an Urgent Public Health Problem.","authors":"Antonia Langfeldt, Jeremy A W Gold, Tom Chiller","doi":"10.1007/s40588-022-00181-3","DOIUrl":"10.1007/s40588-022-00181-3","url":null,"abstract":"Purpose of review: For this review, we use a One Health approach to examine two globally emerging public health threats related to antifungal drug resistance: triazole-resistant Aspergillus fumigatus infections, which can cause a life-threatening illness in immunocompromised hosts, and antifungal-resistant dermatophytosis, which is an aggressive skin infection caused by dermatophyte molds. We describe the state of current scientific knowledge and outline necessary public health actions to address each issue.Recent findings: Recent evidence has identified the agricultural use of triazole fungicides as an important driver of triazole-resistant A. fumigatus infections. Antifungal-resistant dermatophyte infections are likely driven by the inappropriate use of antifungal drugs and antibacterial and corticosteroid creams.Summary: This review highlights the need for a One Health approach to address emerging antifungal resistant infections, emphasizing judicious antifungal use to preserve available treatments; strengthened laboratory capacity to identify antifungal resistance; and improved human, animal, and environmental surveillance to detect emerging resistance, monitor trends, and evaluate the effectiveness of efforts to decrease spread.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"46-51"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10735856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities. 资源有限环境下的全基因组测序:挑战与机遇。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-01-01 DOI: 10.1007/s40588-022-00183-1

Fredrickson B Wasswa, Kennedy Kassaza, Kirsten Nielsen, Joel Bazira

{"title":"MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities.","authors":"Fredrickson B Wasswa, Kennedy Kassaza, Kirsten Nielsen, Joel Bazira","doi":"10.1007/s40588-022-00183-1","DOIUrl":"https://doi.org/10.1007/s40588-022-00183-1","url":null,"abstract":"Purpose of review: The introduction of MinION whole-genome sequencing technology greatly increased and simplified complete genome sequencing in various fields of science across the globe. Sequences have been generated from complex organisms to microorganisms and are stored in genome databases that are readily accessible by researchers. Various new software for genome analysis, along with upgrades to older software packages, are being generated. New protocols are also being validated that enable WGS technology to be rapidly and increasingly used for sequencing in field settings.Recent findings: MinION WGS technology has been implemented in developed countries due to its advantages: portability, real-time analysis, and lower cost compared to other sequencing technologies. While these same advantages are critical in developing countries, MinION WGS technology is still under-utilized in resource-limited settings.Summary: In this review, we look at the applications, advantages, challenges, and opportunities of using MinION WGS in resource-limited settings.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"52-59"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9601454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection. 继发真菌合并感染的COVID-19患者何时开始抗真菌治疗。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2022-01-01 DOI: 10.1007/s40588-022-00184-0

Harnoor Singh Pruthi

{"title":"When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection.","authors":"Harnoor Singh Pruthi","doi":"10.1007/s40588-022-00184-0","DOIUrl":"https://doi.org/10.1007/s40588-022-00184-0","url":null,"abstract":"Purpose of review: Severe-acute respiratory coronavirus 2 (SARS-CoV-2) has been driving the health care delivery system for over 2 years. With time, many issues related to co-infections in COVID-19 patients are constantly surfacing. There have been numerous reports about various fungal co-infections in patients with COVID-19. The extent of severity of fungal pathogens has been recognized as a substantial cause of morbidity and mortality in this population. Awareness, understanding, and a systematic approach to managing fungal co-infections in COVID-19 patients are important. No guidelines have enumerated the stepwise approach to managing the fungal infections co-occurring with COVID-19. This review is intended to present an overview of the fungal co-infections in COVID-19 patients and their stepwise screening and management.Recent findings: The most common fungal infections that have been reported to co-exist with COVID-19 are Candidemia, Aspergillosis, and Mucormycosis. Prevalence of co-infections in COVID-19 patients has been reported to be much higher in hospitalized COVID-19 patients, especially those in intensive care units. While clear pathogenetic mechanisms have not been delineated, COVID-19 patients are at a high risk of invasive fungal infections.Summary: As secondary fungal infections have been challenging to treat in COVID-19 patients, as they tend to affect the critically ill or immunocompromised patients, a delay in diagnosis and treatment may be fatal. Antifungal drugs should be initiated with caution after carefully assessing the immune status of the patients, drug interactions, and adverse effects. The crucial factors in successfully treating fungal infections in COVID-19 patients are optimal diagnostic approach, routine screening, and timely initiation of antifungal therapy.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 4","pages":"60-68"},"PeriodicalIF":5.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10368281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia. 哥伦比亚麦德林两个诊所住院的新冠肺炎成年人的生存率和临床特征比较

IF 3.1

Current Clinical Microbiology Reports Pub Date : 2022-01-01 Epub Date: 2022-04-09 DOI: 10.1007/s40588-022-00179-x

Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García

{"title":"Comparison of Survival and Clinical Profile of Adults with COVID-19 Hospitalized in Two Clinics in Medellín, Colombia.","authors":"Juan Carlos Cataño-Correa, Jaiberth Antonio Cardona-Arias, Jessica Paola Porras-Mancilla, Marcela Tabares-García","doi":"10.1007/s40588-022-00179-x","DOIUrl":"10.1007/s40588-022-00179-x","url":null,"abstract":"Purpose of review: This study compares the survival and clinical profile of hospitalized adults with COVID-19 in two clinics in the city of Medellín, Colombia, with a prospective study with 198 patients in clinic A and 201 in clinic B. Comparisons were made with chi-square and Mann-Whitney U, factors associated with survival were identified with a Cox regression.Recent findings: The proportion of deaths was 7.1% in clinic A with a mean survival of 51.9 days (95% CI = 45-59); in clinic B 13.9% of patients died with mean survival of 37.8 days (95% CI = 32-43). The most prevalent comorbidities were hypertension (41.6%), diabetes (23.8%), obesity (15.0%), hypothyroidism (13.0%), dyslipidemia (11.0%), and chronic lung disease (10.8%) with similar proportions in both clinics. There were also differences by the clinic in the most prevalent complications: bacterial pneumonia (18.8%), acute renal failure (14.3%), and encephalopathy (9.5%). There were no differences in the days of hospitalization, mechanical ventilation (clinic A 23.7% and clinic B 29.4%) and admission to the ICU (25.3% in A and 32.3% in B).Summary: We evidence the heterogeneity of the survival and the clinical profile of the patients who are cared for by two institutions of the same city. These findings demonstrate the need to conduct unique studies for each institution, which poses a significant challenge for hospital epidemiology programs due to the impossibility of extrapolating evidence from other healthcare institutions and the need to implement personalized medicine programs given the clinical diversity of patients hospitalized for COVID-19.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"9 1","pages":"11-19"},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46756479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0